Since the findings of the Second National Acute Spinal Cord Injury Study (NASCIS-2) were published in 1990, 1 use of intravenous high-dose methylprednisolone sodium succinate (MPSS) for the treatment of acute spinal cord injury has been considered standard treatment in the United States and some other countries. [2] [3] [4] The NASCIS-2 concluded that MPSS should be administered if a spinal cord injury patient is seen less than 8 hours after injury. 1 Initially, a bolus dose of 30 mg/kg of body weight should be administered followed by an infusion of 5.4 mg/kg for 23 hours. In Japan, Otani et al 5 also reported the effectiveness of this treatment for the recovery of motor function in patients with acute spinal cord injury. In 1997, the Japanese Ministry of Health and Welfare approved this treatment for patients with acute spinal cord injury within 8 hours after injury, and its effectiveness has been widely recognized by Japanese orthopedic surgeons, neurosurgeons, and physicians treating spinal cord injury at emergency care units. A number of recent papers, however, have strongly criticized the NASCIS-2.
6 -11 A repeated criticism is that the positive benefits that were shown in the NASCIS-2 were based on conclusions drawn from a selected subgroup after the results were analyzed, and not a priori. Actually, we have poorly realized clinical implications that MPSS has beneficial effects on acute spinal cord injury.
The present study, therefore, assessed neurologic recovery 6 weeks and 6 months after high-dose MPSS treatment administered to patients within 8 hours of cervical spinal cord injury in accordance with the NASCIS-2 protocol, and compared it to the neurologic recovery of spinal cord injury patients who received no MPSS treatment. Additionally, complications of high-dose MPSS in patients with acute cervical spinal cord injury were evaluated. pleted spinal cord injury rehabilitation at the Spinal Injuries Center. Two hundred and seventy-eight consecutive acute midto-lower cervical spinal cord injury patients were admitted to the Spinal Injuries Center for 5 years from 1998 to 2002. Among these patients, 70 who were admitted within 7 days after injury and had been followed up at the Spinal Injuries Center for more than 6 months were divided into 2 groups. One group included patients who were treated with MPSS within 8 hours of their injury according to the NASCIS-2 protocol, the other group included patients who were not administered with MPSS at emergency hospitals or the Spinal Injuries Center. The former group, containing 37 patients, was defined as the MPSS group, and the latter, containing 33 patients, was defined as the non-MPSS group. Patients excluded from the present study consisted of those with partially flawed medical records, follow-up of less than 6 months, admission later than 7 days after injury, MPSS or its equivalent administration nonconforming to NASCIS-2 protocol, bone fracture of extremities, death with complications, brain injury, multiple spinal cord injury, mental disturbance, and peripheral nerve injury (Appendix available for viewing on ArticlePlus only). Spine injury patients without paralysis were also excluded.
Materials and Methods
The American Spinal Injury Association (ASIA) impairment scale and the ASIA motor score (range from 0 to 100) for each patient was based on the neurologic findings documented at the time of admission to the Spinal Injuries Center, and followed prospectively at intervals from the point of admission to the 6-week and 6-month follow-ups. In this study, sensory function was not evaluated because it is difficult to assess correctly. Neurologic recovery was defined as an improvement in motor score by subtracting the baseline score from the 6-week and 6-month follow-up scores.
The neurologic levels of injury were recorded as the most caudal myotomal levels of intact motor function in patients with complete motor loss at admission and follow-up periods. Improvements of myotomal levels between the MPSS (n ϭ 15) and the non-MPSS (n ϭ 21) groups were compared. The improvements in myotomal levels were defined by subtracting the baseline levels from the 6-week and 6-month follow-up levels.
Early complications within 6 weeks of high-dose MPSS therapy were compared with those of no MPSS therapy in patients with acute cervical spinal cord injury.
Nominal data were analyzed by the 2 test. Continuous data were analyzed by the Mann-Whitney U test. All tests were performed at a significance level of 0.05.
Results
There were 37 patients in the MPSS group (32 men, 5 women; mean age 50.2 years). There were 33 patients in the non-MPSS group (30 men, 3 women; mean age 51.6 years). There was no significant difference in sex ratio or age between the groups (Table 1 ). All patients had neurologic deficits of varying degrees (ASIA impairment scale). There were significant differences in the patients with incomplete paralysis (i.e., containing ASIA impairment scale B, C, and D) between the groups (P ϭ 0.02).
The patients in the MPSS group had significantly more improvement in motor score than those in the non-MPSS group at 6 weeks after injury. Improvement in motor score at 6 months after injury was also greater in the MPSS group. However, among the patients with complete paralysis (i.e., ASIA impairment scale A) at the time of admission to the Spinal Injuries Center, patients in the MPSS group did not show significantly more change in motor score than patients in the non-MPSS group. Meanwhile, among the patients with incomplete paralysis (i.e., containing ASIA impairment scale B, C, and D) at admission, the patients in the MPSS group had significantly more improvement in motor score than those in the non-MPSS group at 6 weeks after injury. Improvement in motor score at 6 months after injury was also greater in the MPSS group (Table 2) .
There were no significant differences between the MPSS and non-MPSS groups with regard to improvement in myotomal level ( Table 3) .
The non-MPSS group had more early complications than the MPSS group, although the differences between the 2 groups showed no statistical significance. Pulmonary complications and infections in patients in the non-MPSS group were more than those in the MPSS group, but there were no significant differences (Table 4) .
Of our 278 admissions with acute cervical spinal cord injury, 4 patients died. Two patients who were not administrated with MPSS died within 3 weeks after their injuries: one died of pneumonia, and the other died of combined abdominal injury. Another 2 patients who were administrated with low-dose MPSS nonconforming to the NASCIS-2 protocol died of pneumonia at about 3 months after their injuries. 
Discussion
The precise mechanisms by which MPSS affect neuroprotection are not completely understood, but MPSS is thought to improve extracellular calcium ion recovery and, therefore, produce a local vasodilation response in the contused spinal cord. 12 MPSS is also thought to inhibit lipid peroxidation and hydrolysis at the injured region of the spinal cord. 13 As the first clinical study to demonstrate the efficacy of a pharmacologic agent in the treatment of spinal cord injury, the NASCIS-2 trial established the widespread use of MPSS. 1 In the NASCIS-2, a total 487 patients were randomized within 12 hours of injury to MPSS, naloxone, or placebo. This trial used an initial 30-mg/kg bolus of MPSS followed by a 23-hour infusion of 5.4 mg/kg per hour. MPSS administered within 8 hours of injury resulted in statistically significant motor and sensory recovery in both complete and incomplete spinal cord injuries when evaluated at 6 weeks, 6 months, and 1 year after injury. 1,14 -16 Subsequently, the NASCIS-3 was then performed to compare different durations of MPSS treatment and also to evaluate the efficacy of tirilazad mesylate. 17 A total of 499 patients received the initial 30 mg/kg bolus of MPSS within 8 hours of injury and were randomized to 24 or 48-hour MPSS infusions or to tirilazad mesylate for over 48 hours. The motor and sensory recovery was similar among all study arms when treatment was initiated within 3 hours after injury, suggesting that the 24-hour infusion of MPSS was sufficient in these patients. However, when initiated between 3 and 8 hours, there appeared to be a benefit to extending the MPSS infusion to 48 hours. Although the Food and Drug Administration has not granted an "indication of use" to MPSS for treating spinal cord injury, the standard treatment for spinal cord injury is administration of MPSS according to the NASCIS-2 and NAS-CIS-3 regimens in the United States. 2 Canada and European countries show the same patterns as well. 3, 4 In Japan, only the NASCIS-2 regimen is officially approved and applied for patients with acute spinal cord injury within 8 hours after injury.
However, high-dose MPSS remains a controversial treatment. Many recent papers have strongly criticized the NASCIS-2 and NASCIS-3. 6 -11,18 A number of authors have published in-depth analyses of these studies. The primary questioning of the validity of these studies relates to the fact that in the NASCIS-2, the primary outcome analysis of motor and sensory recovery was negative, and only after a post hoc analysis of patients receiving MPSS before and after 8 hours was an arguably small yet statistically significant benefit accrued. Similarly, the primary outcome of the NASCIS-3 was negative, but with a post hoc analysis delineating a benefit of 48-hour MPSS treatment for those in whom treatment was initiated after 3 hours. And it was found that wound infection rates, pulmonary embolism, severe pneumonia and sepsis, and even death secondary to respiratory complications appeared to be higher with MPSS use, in particular with the 48-hour regimen of the NASCIS-3. From evidence-based approaches, these authors have concluded that the use of high-dose MPSS administration according to the NASCIS-2 and NASCIS-3 is not recommended in the treatment of acute spinal cord injury. 6 -11,18 However, we advocate that the NASCIS-2 and NASCIS-3 should be argued separately. With certainty, the NASCIS-3 regimen in the management of acute spinal cord injury cannot be supported because of a higher incidence of severe infectious complications in patients with 48 hours of MPSS. 17 Indeed, the primary outcome analysis was negative in the NASCIS-2, but after intent-to-treat analysis, patients receiving MPSS within 8 hours after injury had statistically greater motor and sensory improvement than those receiving placebo at 6 months and 1 year. 1, 14 In addition, medical complication and mortality rates were similar in the MPSS treated group of patients compared with the placebo group. 14 Fehlings 19 suggested that MPSS be recommended at the level of a guideline (class II evidence) for acute, nonpenetrating spinal cord injury within 8 hours of trauma. In Japan, Otani et al 5 also reported the effectiveness of this treatment for the recovery of motor function in patients with acute spinal cord injury. George et al, 20 however, reported no significant differences in clinical improvement in the outcome of spinal cord injury between the MPSS and placebo groups. Pollard and Apple 21 also reported that high-dose MPSS administration was not associated with improved neurologic outcomes in patients with incomplete cervical spinal cord injuries. The present study showed that the patients with acute cervical spinal cord injury receiving MPSS within 8 hours after injury according to the NASCIS-2 had statistically greater motor improvement at 6 weeks and 6 months than those not receiving MPSS. Statistically significant improvement of motor score was particularly shown in the patients with incomplete cervical spinal cord injuries. Our data did not justify the use of MPSS in complete cervical spinal cord injury patients. Probably, the effects of MPSS to minimize secondary injury and protect the neural elements that initially survived the mechanical injury may not be sufficient for complete spinal cord injury because the energy delivered to the spinal cord and the resultant disrupted tissue area at primary injury may be larger in patients with complete injury than in patients with incomplete injury. The reason why there is a significant improvement in ASIA motor score without improvement in myotomal level is uncertain. Probably, improvement in ASIA motor score may represent recovery in the function of long spinal tract. On the other hand, improvement in myotomal levels may represent recovery in the function of segmental motor neuron cells at the level of injury.
Gerndt et al 22 reported no significant difference in the overall rate of complication, although a significant increase in pneumonia occurred in the MPSS group. Pointillart et al 23 noted a high incidence of hyperglycemia in almost half of their MPSS treated patients that were analyzed for complications. Matsumoto et al's 24 small series that specifically looked at early complications failed to identify a statistically significant increased rate of complications from the NASCIS-2 regimen, despite significant differences in pulmonary and gastrointestinal negligible complications and a nonsignificant trend toward sepsis with MPSS. Ishida and Tominaga 25 described that there were no acute infections, pneumonia, urinary tract infections, or late-term necrosis of femoral head, and no clinically significant changes in blood glucose in MPSS treated patients with acute central cervical spinal cord injury with motor and sensory impairment involving only upper extremities. The current study reported no significant difference in the overall incidence of early complications between MPSS and non-MPSS patients.
As described above, the present study showed that high-dose MPSS therapy according to the NASCIS-2 was effective for neurologic improvement among the patients with incomplete cervical spinal cord injury and no correlation with early complications in acute cervical spinal cord injury. However, MPSS does not have strong enough power to improve the recovery of patients with ASIA impairment scale. We hope that other neuroprotective agents will enter into clinical practice in the near future. Although our data were gathered at a large spinal cord injury center in Japan, the present study has 3 serious limitations. One is the lack of sensory testing. We recognize adequately the importance of assessing sensory function with spinal cord injured patients. But it was actually very difficult to assess sensory function with cervical spinal cord injured patients correctly. Consequently, we decided that sensory function would not be evaluated in this study. The other 2 are its small size and retrospective nature. Further prospective randomized controlled studies are needed to conclude this issue definitively.
Conclusions
The results of the present study indicate that MPSS should be administered according to the NASCIS-2 protocol if patients with incomplete cervical spinal cord injury are seen less than 8 hours after their injury. Although the current study showed that the NASCIS-2 protocol does not increase the morbidity rate of early complications in patients with acute cervical spinal cord injury, physicians should check patients' previous diseases such as allergies to steroid drugs, diabetes mellitus, and serious infections before MPSS administration to prevent severe complications.
Key Points
• In this study, we evaluated the recovery of motor function in patients with acute cervical spinal cord injury after receiving a high dose of MPSS within 8 hours of injury and the early complications of highdose MPSS on the patients.
• The ASIA motor scores in the MPSS group were improved more significantly than those in the non-MPSS group at 6 weeks and 6 months after injury.
• The present study showed that high-dose MPSS therapy according to the NASCIS-2 had no correlation with early complications of acute cervical spinal cord injury.
